Cellular therapy by allogeneic macrophages against visceral leishmaniasis: Role of TNF-α

• Macrophage acts as an effector cell in leishmaniasis without T cell help.
• Allogeneic and xenogeneic macrophages kill intracellular Leishmania donovani.
• TNF-α play a major role in leishmanicidal effects by monocytes/macrophages in vitro.
• Allogeneic macrophages significantly reduces parasite burden in infected mice.
• Elevated serum TNF-α level in mice treated with allogeneic macrophages.

Tumor necrosis factor α (TNF-α) is an essential player in infection with Leishmania, controlling inflammatory lesion and parasite killing. We recently have shown the leishmanicidal activity of transmembrane form of TNF (mTNF) derived from allogeneic natural killer (NK) cells in experimental visceral leishmaniasis. Allogeneic macrophages and human monocytes derived mTNF has significantly higher antileishmanial activity compared to allogeneic NK cells. Unlike NK cells, syngeneic macrophages also possess antileishmanial activity, although degree of activity is significantly less compared to allogeneic macrophages. Cellular therapy by intravenous transfer of allogeneic macrophages enhances leishmanicidal effect against the established infection in susceptible animal by reducing the splenic parasite burden to 28.3 ± 4.71 × 105 compared to 256.00 ± 17.36 × 105 in control group. In vivo treatment with anti-mouse TNF-α reduces the therapeutic efficacy of the allogeneic macrophages by increasing the parasite load in spleen of infected mice. These results demonstrated that allogeneic and xenogeneic macrophages induce cytokine mediated protective mechanism against infected macrophages via TNF-α in vitro and, possibly in vivo. The macrophage mediated protective role in absence of T cell help demonstrate an unique property of the mononuclear phagocytes in controlling infection and inflammation in visceral leishmaniasis, despite being acts as a host cell for the same parasite.

Figure optionsDownload as PowerPoint slide